AxoGen (AXGN) Projected to Announce Quarterly Earnings on Wednesday

AxoGen (NASDAQ:AXGN) is anticipated to announce its Q2 2026 results before the market opens on Wednesday, July 29th. Analysts expect AxoGen to announce earnings of $0.09 per share and revenue of $67.0990 million for the quarter. Individuals may review the information on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Wednesday, July 29, 2026 at 8:00 AM ET.

AxoGen (NASDAQ:AXGN) last announced its quarterly earnings results on Tuesday, April 28th. The medical equipment provider reported $0.07 EPS for the quarter, missing the consensus estimate of $0.12 by ($0.05). The firm had revenue of $61.46 million during the quarter, compared to the consensus estimate of $57.85 million. AxoGen had a negative net margin of 13.21% and a negative return on equity of 9.63%. On average, analysts expect AxoGen to post $-0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

AxoGen Stock Up 2.0%

AXGN opened at $40.26 on Wednesday. The firm has a market capitalization of $2.14 billion, a P/E ratio of -62.91 and a beta of 1.09. AxoGen has a one year low of $11.61 and a one year high of $46.95. The company has a fifty day moving average price of $42.25 and a 200-day moving average price of $36.93. The company has a debt-to-equity ratio of 0.08, a current ratio of 7.10 and a quick ratio of 5.33.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on AXGN. Citizens Jmp upped their target price on AxoGen from $42.00 to $50.00 and gave the stock a “market outperform” rating in a research note on Wednesday, April 29th. Citigroup reissued an “outperform” rating on shares of AxoGen in a report on Wednesday, April 29th. Wells Fargo & Company upped their price objective on shares of AxoGen from $40.00 to $48.00 and gave the stock an “overweight” rating in a research report on Wednesday, April 29th. Raymond James Financial reaffirmed an “outperform” rating and issued a $48.00 target price on shares of AxoGen in a research note on Wednesday, April 29th. Finally, Zacks Research upgraded shares of AxoGen from a “strong sell” rating to a “hold” rating in a research report on Friday, May 29th. Nine research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $46.50.

Insider Activity at AxoGen

In related news, Director John Johnson sold 11,050 shares of the firm’s stock in a transaction dated Thursday, May 7th. The stock was sold at an average price of $43.26, for a total transaction of $478,023.00. Following the transaction, the director directly owned 11,050 shares of the company’s stock, valued at approximately $478,023. This trade represents a 50.00% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Kathy Johnson Weiler sold 16,344 shares of the business’s stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $44.09, for a total value of $720,606.96. Following the completion of the sale, the director owned 16,344 shares of the company’s stock, valued at $720,606.96. The trade was a 50.00% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 29,041 shares of company stock valued at $1,268,792. Corporate insiders own 2.44% of the company’s stock.

Institutional Trading of AxoGen

Several institutional investors have recently added to or reduced their stakes in AXGN. First Light Asset Management LLC grew its holdings in shares of AxoGen by 1.2% in the second quarter. First Light Asset Management LLC now owns 4,529,243 shares of the medical equipment provider’s stock worth $49,142,000 after purchasing an additional 55,028 shares during the last quarter. Morgan Stanley raised its position in shares of AxoGen by 6.5% in the 4th quarter. Morgan Stanley now owns 2,586,870 shares of the medical equipment provider’s stock worth $84,668,000 after acquiring an additional 157,029 shares in the last quarter. Balyasny Asset Management L.P. raised its position in shares of AxoGen by 183.9% in the 2nd quarter. Balyasny Asset Management L.P. now owns 1,931,158 shares of the medical equipment provider’s stock worth $20,953,000 after acquiring an additional 1,250,968 shares in the last quarter. Wasatch Advisors LP boosted its position in shares of AxoGen by 14.3% during the third quarter. Wasatch Advisors LP now owns 1,639,351 shares of the medical equipment provider’s stock valued at $29,246,000 after purchasing an additional 205,569 shares in the last quarter. Finally, Soleus Capital Management L.P. grew its stake in AxoGen by 0.9% in the second quarter. Soleus Capital Management L.P. now owns 1,459,395 shares of the medical equipment provider’s stock worth $15,834,000 after purchasing an additional 13,278 shares during the period. 80.29% of the stock is currently owned by hedge funds and other institutional investors.

About AxoGen

AxoGen, Inc is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen’s offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.

The company’s core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue.